Options for Restructuring the Safe and Drug-Free Schools and Communities Act

Report with Background Papers and Focus Group Summary

by Peter Reuter, P. Mike Timpane, Mina Kimmerling, Melissa A. Bradley, David L. Kirp, Aaron D. Good, Paul Sandhu, Lawrence W. Sherman, Jackson Toby

Download

Full Document

FormatFile SizeNotes
zip file 0.9 MB

The file(s) provided above are ZIP-formatted archives, which most modern systems can natively unpack. If your computer does not unpack the archive when you double-click it, you may need to use a separate decompression program such as UnZip.

Purchase

Purchase Print Copy

 FormatList Price Price
Add to Cart Paperback194 pages $20.00 $16.00 20% Web Discount

This report contains all the outputs of a project undertaken to review the structure and performance of the Safe and Drug-Free Schools and Communities Act (SDFSCA) and to assess options for strengthening it. As part of this study, a conference was held at which practitioners, researchers, and government officials considered the findings and conclusions presented in three commissioned papers, the proceedings of focus groups of knowledgeable practitioners in two school districts, and a review of the literature describing the program established by SDFSCA and its performance to date. This volume contains the executive summary of the study, the background paper prepared to provide information for the conference participants, a summary of the focus group discussions, and the commissioned papers.

Table of Contents

  • Preface

  • Options for Restructuring the Safe and Drug-Free Schools and Communities Act

  • Characteristics and Challenges of the Safe and Drug-Free Schools and Communities Act: a Historical Analysis

  • Focus Groups: Safe and Drug-Free Schools Programs

  • A Quarter-Century's Experience with Sex, Alcohol, Tobacco and Drug Education in the Schools

  • Knowledge, Democracy, and Evidence-Based Government

  • Obstacles to Safe and Drug-Free Schools: Trapped Kids, Competing Curricula, and Scarce Guardians

The research described in this report was performed under the auspices of RAND's Drug Policy Research Center.

This report is part of the RAND Corporation Monograph report series. The monograph/report was a product of the RAND Corporation from 1993 to 2003. RAND monograph/reports presented major research findings that addressed the challenges facing the public and private sectors. They included executive summaries, technical documentation, and synthesis pieces.

Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit www.rand.org/about/principles.

Permission is given to duplicate this electronic document for personal use only, as long as it is unaltered and complete. Copies may not be duplicated for commercial purposes. Unauthorized posting of RAND PDFs to a non-RAND Web site is prohibited. RAND PDFs are protected under copyright law. For information on reprint and linking permissions, please visit the RAND Permissions page.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.